Bioactivation at Scale: From Discovery to Manufacturing Excellence in the Next Generation of Natural Products
Day 3 Supply & Formulation Excellence Stage
08/10/2026 10:00 - 10:25am
Contributors
Cynthia Hunefeld : Founder & CEO - Evithé Biotechnology
Evithé Biotechnology has discovered a proprietary bio-activation and extraction process that unlocks an exceptional new class of anti-inflammatory compound from ginger — Carelwon®, up to 105× more potent than standard ginger, curcumin, and berberine across six inflammatory pathways, and 13× stronger than CBD in the gold-standard preclinical arthritis models.
The whole bio-activated extract outperforms isolated compounds in vitro, revealing a synergy standard extraction methods have long overlooked. Developed for the 1 in 5 people worldwide suffering from chronic inflammation, this discovery began as a personal mission by the founder to find a solution for her father. Built over 15+ years of research with Victoria University of Wellington and MRINZ, Carelwon® has completed Phase 1 safety and tolerability testing (n=50, zero adverse events). This presentation traces the journey from discovery to scale.